Publications by authors named "Reyes Sancho-Tello"
Background: Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been identified. Type and number of somatic mutations have been associated with prognosis and response to therapies in MDS patients.
View Article and Find Full Text PDFObjective: To assess the generation of reactive oxygen species (ROS) and the involvement of the main antioxidant pathways in low/intermediate-1-risk myelodysplastic syndromes (MDS) with iron overload (IOL).
Methods: We examined the levels of superoxide anion (O), hydrogen peroxide (HO), antioxidants (glutathione, GSH; superoxide dismutase, SOD; catalase, CAT; and glutathione peroxidase, GPx), mitochondrial membrane potential (ΔΨm), and by-products of oxidative damage (8-isoprostanes and 8-oxo-7,8-dihydro-2'-deoxyguanosine, 8-oxo-dG) in 42 MDS patients (28 without IOL at diagnosis, and 14 who developed IOL) and 20 healthy subjects.
Results: Patients with IOL showed higher O levels (39.
Article Synopsis
- Chronic myelomonocytic leukemia (CMML) is a complex blood cancer with varying outcomes, and researchers have developed a prognostic scoring system (CPSS) based on clinical factors and genetics to predict patient outcomes.
- A study involving sequencing of 38 genes revealed that a high percentage of CMML patients have somatic mutations, which contribute significantly to the variability in disease characteristics and survival rates.
- The new clinical/molecular model (CPSS-Mol), which combines genetic factors, blood count data, and treatment needs, effectively categorizes patients into risk groups with distinct survival outcomes and can guide clinical decisions and future research.
Background: The prognostic value of cytogenetic findings in chronic myelomonocytic leukemia is unclear. Our purpose was to evaluate the independent prognostic impact of cytogenetic abnormalities in a large series of patients with chronic myelomonocytic leukemia included in the database of the Spanish Registry of Myelodysplastic Syndromes.
Design And Methods: We studied 414 patients with chronic myelomonocytic leukemia according to WHO criteria and with a successful conventional cytogenetic analysis at diagnosis.